<DOC>
	<DOCNO>NCT00953927</DOCNO>
	<brief_summary>This Phase II double-blinded randomize controlled evaluation safety , immunogenicity efficacy MVA85A/AERAS-485 Bacillus Calmette-Gu√©rin ( BCG ) vaccinate infant without tuberculosis HIV infection . This study plan enroll 2784 infant ( 126 182 day age ) receive study vaccine control follow 15 - 36 month . The study conduct single site South Africa .</brief_summary>
	<brief_title>A Study MVA85A Healthy Infants</brief_title>
	<detailed_description>This Phase II double-blinded randomize controlled evaluation safety , immunogenicity efficacy MVA85A/AERAS-485 BCG vaccinate infant without tuberculosis HIV infection . Infants ( 126 182 day ) receive intradermal ( ID ) study vaccine ( MVA85A/AERAS-485 Candida skin test antigen control ) . All infant follow least 15 month last infant enrol study . Given completion enrollment 21 month , total duration follow-up infant schedule least 15 month 36 month . Infants follow entire duration study development tuberculosis serious adverse event . On enrollment study , eligible infant assign study group start Study Group 1 randomize 1:1 ratio within study group receive either MVA85A/AERAS-485 Candida skin test antigen control . Infants assign safety cohort ( Study Group 1 ) , 1 3 immunological assay evaluation group ( Study Groups 2-4 ) , finally remainder infant assign correlate protection cohort ( Study Group 5 ) . At least 330 infant randomize Study Group 1 , 50-60 infant Study Groups 2-4 , remain infant randomize Study Group 5 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Age 126 182 day day randomization ( Study Day 0 ) 2 . Written inform consent obtain parents/guardian 3 . Weight : chart &gt; 3rd percentile Study Day 0 , &lt; 3rd percentile , infant show stable growth pattern 4 . BCG vaccination within 7 day birth 5 . Generally good health confirm medical history physical examination within 35 day prior Study Day 0 6 . Must receive ageappropriate dos pneumococcal vaccine recommend South African Department Health injection within 14 day prior Study Day 0 7 . Ability complete followup period require protocol 8 . Completed simultaneous enrollment Aeras Vaccine Development Registry protocol 1 . Acute illness Study Day 0 2 . Fever &gt; =37.5 degrees Celsius Study Day 0 3 . Evidence significant active infection Study Day 0 4 . Received Expanded Program Immunization ( EPI ) within 14 day prior Study Day 0 5 . Historical virological evidence individual maternal human immunodeficiency virus ( HIV1 ) infection 6 . History allergic disease reaction likely exacerbate component study vaccine 7 . Previous medical history , evidence , intercurrent illness may compromise safety infant study 8 . Evidence chronic hepatitis cause 9 . History evidence systemic disease physical examination acute , chronic intercurrent illness , opinion investigator , may interfere evaluation safety immunogenicity vaccine 10 . History known tuberculosis treatment tuberculosis 11 . Shared residence since birth individual active tuberculosis antituberculosis treatment le 2 month</criteria>
	<gender>All</gender>
	<minimum_age>126 Days</minimum_age>
	<maximum_age>182 Days</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>